Cytochroma
Kingston
About Cytochroma
Cytochroma is a clinical stage specialty pharmaceutical company that designs, develops and commercializes prescription products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company has an advanced portfolio of new therapies designed to safely and effectively treat patients with vitamin D insufficiency and SHPT associated with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing novel therapies to treat elevated blood phosphorus levels (hyperphosphatemia) in order to improve the control of SHPT in CKD patients.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $75.8M
- Funding stage: M&A
- Last round: Series C (Jul 2008)
- Website: cytochroma.com
- Phone: 847-236-7707
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Canonical: https://fsome.com/organization/cytochroma-2759832 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.